U.S. Markets open in 7 hrs 27 mins

IntelGenx Technologies Corp. (IGX.V)


TSXV - TSXV Delayed Price. Currency in CAD
Add to watchlist
0.99+0.04 (+4.21%)
At close: 3:37PM EDT
People also watch
ICO.VDMA.VBTI.VRVV.VIGXT

IntelGenx Technologies Corp.

6420 Abrams
Saint-Laurent, QC H4S 1Y2
Canada
514-331-7440
http://www.intelgenx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees25

Key Executives

NameTitlePayExercisedAge
Dr. Horst G. Zerbe Ph.D.Founder, Chairman, CEO, Pres and Chairman of Scientific Advisory Board285.75kN/A70
Mr. Andre Godin CPA, CAChief Financial Officer and Exec. VP247.14kN/A53
Mr. John Durham B.Sc.VP of Operations180.21kN/A62
Dr. Dana Matzen PH.D.VP of Bus. and Corp. Devel.94.99kN/A39
Ms. Nadine Paiement M.Sc.Vice-Chair of Scientific Advisory Board and VP of R&D118.84kN/A40
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

IntelGenx Technologies Corp., a drug delivery company, develops novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company’s products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2012 for schizophrenia; and INT0043/2015 to treat mild cognitive impairment and Alzheimer’s disease. It is also developing various products, including INT0037/2013, INT0039/2013, INT0040/2014, INT0041/2015, INT0042/2015, and INT0044/2016 based on three delivery platform technologies, which consist of VersaFilm, an oral film technology; VersaTab, a multilayer tablet technology; and AdVersa, a mucoadhesive tablet technology. The company has co-development and commercialization agreements with RedHill Biopharma Ltd.; Par Pharmaceutical Companies, Inc.; and Endo Ventures Ltd., as well as a licensing, development, and supply agreement with Chemo Group. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Saint-Laurent, Canada.

Corporate Governance

IntelGenx Technologies Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.